ArticleDiscover oncology2025
Pan-cancer multi-omics analysis reveals IQCE as a malignant cell-restricted oncogenic biomarker driving immunosuppression and chemoresistance in cutaneous melanoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Data-intensive immune network modelling for One Health.Briefings in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous melanoma (SKCM) presents significant therapeutic challenges due to heterogeneity and acquired resistance to targeted and immune checkpoint blockade therapies. IQCE, a ciliary scaffold protein, has poorly defined roles in cancer. Its clinical significance, molecular mechanisms, and impact on the tumor microenvironment (TME) and therapy response are largely unknown.
methodsWe conducted a comprehensive pan-cancer multi-omics analysis of IQCE using genomic, transcriptomic, proteomic, spatial transcriptomic, single-cell transcriptomic, and pharmacogenomic datasets. Analyses included differential expression, survival, pathway enrichment, immune deconvolution, cellular localization, and drug sensitivity prediction.
resultsIQCE was significantly upregulated in multiple solid tumors, most notably cutaneous melanoma (SKCM), liver hepatocellular carcinoma (LIHC), and glioblastoma (GBM), demonstrating strong diagnostic value. High IQCE independently predicted poor prognosis in SKCM. Mechanistically, elevated IQCE correlated with suppression of immune pathways (e.g., cytokine signaling), inhibition of apoptosis, and activation of RAS/MAPK/RTK oncogenic signaling. Single-cell and spatial analyses confirmed IQCE enrichment specifically within malignant cells. High IQCE was associated with broad chemoresistance. Pharmacogenomic profiling revealed a consistent inverse correlation between IQCE expression and sensitivity to the p53-reactivating compound RITA.
conclusionIQCE emerges as a novel oncogene-associated biomarker with significant diagnostic and prognostic utility, particularly in SKCM. It promotes an immunosuppressive TME and oncogenic signaling while being localized to malignant cells. Although associated with chemoresistance, the vulnerability of IQCE-high tumors to RITA offers a promising therapeutic strategy. IQCE represents a compelling target for precision oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.